Natixis Advisors L.P. Sells 13,902 Shares of argenx SE (NASDAQ:ARGX)

Natixis Advisors L.P. lowered its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 49.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,490 shares of the company's stock after selling 13,902 shares during the period. Natixis Advisors L.P.'s holdings in argenx were worth $5,512,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ARGX. Raymond James Financial Services Advisors Inc. raised its stake in shares of argenx by 30.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 14,470 shares of the company's stock valued at $5,505,000 after acquiring an additional 3,374 shares in the last quarter. abrdn plc purchased a new position in argenx in the fourth quarter worth approximately $27,952,000. China Universal Asset Management Co. Ltd. increased its position in shares of argenx by 388.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,719 shares of the company's stock valued at $1,415,000 after purchasing an additional 2,958 shares during the last quarter. RTW Investments LP lifted its position in shares of argenx by 5.2% during the 3rd quarter. RTW Investments LP now owns 507,195 shares of the company's stock worth $249,352,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Townsquare Capital LLC grew its stake in shares of argenx by 96.6% during the third quarter. Townsquare Capital LLC now owns 3,442 shares of the company's stock worth $1,692,000 after purchasing an additional 1,691 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

NASDAQ:ARGX traded down $7.92 during trading hours on Friday, hitting $374.63. The company's stock had a trading volume of 369,022 shares, compared to its average volume of 262,569. argenx SE has a 52-week low of $327.73 and a 52-week high of $550.76. The business's 50-day moving average is $382.64 and its two-hundred day moving average is $409.12. The company has a market capitalization of $22.26 billion, a PE ratio of -66.19 and a beta of 0.67.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.33). The company had revenue of $412.51 million during the quarter, compared to analysts' expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the prior year, the business earned ($0.52) EPS. As a group, analysts predict that argenx SE will post -2.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ARGX. Truist Financial lifted their price target on argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. Wells Fargo & Company upped their target price on shares of argenx from $472.00 to $478.00 and gave the company an "overweight" rating in a report on Tuesday, February 20th. Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the company a "sector perform" rating in a research report on Tuesday, March 26th. Wolfe Research began coverage on shares of argenx in a research report on Thursday, February 15th. They issued a "peer perform" rating for the company. Finally, HC Wainwright dropped their price objective on argenx from $451.00 to $448.00 and set a "buy" rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of "Moderate Buy" and a consensus price target of $527.84.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.